Update on Cancer Immunotherapy and Targeted Therapies

Dear Colleague,

Cancer remains the second leading cause of death worldwide. Immunotherapy, based on the use of novel human monoclonal antibodies (mAbs) with antitumor or immunomodulatory activity, is an increasingly important strategy for cancer treatment. Targeted drugs can be directed against tumor-associated antigens (TAA) overexpressed on the cell surface of tumor cells, either to inhibit their oncogenic function or to specifically deliver toxic compounds.

Indeed, these two approaches also face challenges related to drug selection and drug resistance, the optimal combination ratio of immunotherapy and chemoradiotherapy, toxic and side effects of combination therapy, future perspectives of immune checkpoint inhibitors, new predictive biomarkers for treatment response, etc.

The aim of this Special Issue is to showcase state-of-the-art research and comprehensive reviews focusing on innovative anti-cancer strategies. We welcome submissions on all aspects of combinatorial approaches to cancer immunotherapy, highlighting problems, solutions and future directions in the development of novel therapeutic combinatorial approaches.

Dr. Wenpan Li
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.